Immunotherapy for downstaging of locally advanced mismatch repair deficient colorectal cancer: A prospective institutional case series.

Current advances and future directions of combined ICIs and TILs in solid tumors.

Practical management of rheumatic immune-related adverse events occurring with immune checkpoint inhibitors: A narrative review.

Recent advancements highlight promising outcomes with immune checkpoint inhibitors (ICIs) when combined with concurrent chemoradiotherapy (CCRT) or chemotherapy in the treatment of locally advanced cervical cancer (LACC). This systematic review and meta-analysis aimed to assess the efficacy and safety of ICIs combined with CCRT/chemotherapy in patients with LACC. We searched PubMed, Embase, Cochrane and ClinicalTrials.gov for randomized controlled trials (RCTs) and non-RCTs assessing the efficacy and safety of ICIs plus CCRT/chemotherapy in patients with LACC. All analyses were performed in R software (v.4.4.0). Our systematic review and meta-analysis included 3 RCTs and 4 observational studies, corresponding to 1,250 patients. The 1-year progression-free survival (PFS) was 78% (95% confidence interval [CI]=75-80, I²=0%), while the 1-year overall survival (OS) reached 93% (95% CI=89-95, I²= 50%). The objective response rates were 88% (95% CI=74-95, I²=74%). We performed a comparative analysis of PFS and OS using data from the 2 RCTs. The results indicated that the ICI plus CCRT group had a significantly lower risk of disease progression or death compared to the CCRT group alone (PFS: hazard ratio [HR]=0.76, 95% CI=0.64-0.91, I²=4%; OS: HR=0.76, 95% CI=0.58-0.98, I²=0%), representing an approximate 25% reduction in risk. The analysis of grade ≥3 adverse events revealed the low incidences, with none exceeding 15%. Our findings suggest that ICIs are effective and safe to use with CCRT/chemotherapy in LACC patients. Further RCTs are needed to confirm these findings. International Prospective Register of Systematic Reviews Identifier: CRD42024576145.

Chimeric antigen receptor T-cell therapy for solid tumors: A review of the intricate mechanisms and potential strategies.

Nanoparticles-mediated intratumoral gene editing targeting PD-L1 and Galectin-9 for improved cancer immunotherapy.

Immune-mediated diarrhea and colitis (IMDC) is a very common and severe toxicity to immune checkpoint inhibition that has generated a lot of scientific interest. The current guidelines do not capture the most recent literature on this disease entity, and few reviews if any have been published that describe the advances made in our understanding of IMDC. As more and more patients are being treated with immune checkpoint inhibitors (ICIs), it becomes essential to optimize treatment algorithms for ICI-related toxicities, especially IMDC. In our review, we discuss the findings of recent studies on IMDC epidemiology including incidence and risk factors, evaluation and treatment modalities, and surveillance and long-term outcomes. We note that while much has been learned regarding disease epidemiology and the utility of stool biomarkers over clinical symptoms, there remains a paucity of data where IMDC treatment options and long-term IMDC outcomes and surveillance is concerned. Our results highlight the most recent advances in our knowledge of IMDC and allow us to propose a management algorithm that improves on prior guidelines for IMDC by incorporating new study findings.

Platinum-based chemotherapy resistance is one of the main contributors to the mortality of Ovarian Cancer (OC). It is believed that sensitive biomarkers for identifying the population that is platinum-resistant are urgently needed. This study aims to develop a platinum-resistance gene-based signature to predict OC patients' responses to platinum drugs as well as survival outcomes. A platinum-resistance-related gene model was built by bioinformatics analysis. Then, its predictive power was internally validated. Continually, a nomogram was constructed to confirm the model's predictive ability. Afterward, GSEA was used to explore our model's potential functions. The ESTIMATE, CIBERSORT, TIMER, and ssGSEA were applied to estimate immune conditions. Then, somatic mutation and drug sensitivity were also analyzed. Finally, to gain insights into the roles of targeted genes in drug sensitivity, patient-derived tumor organoids (PDOs) validation was performed. Nine platinum-resistance-related genes, including SLC22A2, TAP1, PC, MCM3, GTF2H2, FXYD5, SUPT6H, IGKC, and MATN2, were anchored to build the predictive model, which was well internally validated. Subsequently, GSEA unveiled that our model genes enriched in the Hedgehog signaling pathway. The predictive signature was associated with immune checkpoint inhibitors such as PD-1, PD-L1, and CTLA4, guiding immunotherapy applications for OC patients. Drugs such as dasatinib, midostaurin, metformin, MK-2206, and mitomycin C might also benefit OC patients with different risk scores. PDOs showed patients with high-risk scores were more resistant to cisplatin than patients with low-risk scores. The platinum-resistance-related gene signature (SLC22A2, TAP1, PC, MCM3, GTF2H2, FXYD5, SUPT6H, IGKC, and MATN2) is valuable for prognosis prediction and guidance of treatment choices for OC patients.

Survival outcomes of the use of adjuvant chemotherapy in resected esophagus cancer after neoadjuvant chemoradiotherapy.

Artificial Intelligence for Predictive Diagnostics, Prognosis, and Decision Support in MASLD, Hepatocellular Carcinoma, and Digital Pathology.

Cationic LIposome capsulated CRISPR-Cas13a Kit (CLICK) for in situ detection of circulating PD-L1 mRNA in single EV towards monitoring of immunotherapy efficacy.

Exploring radiation pneumonitis associated with immune checkpoint inhibitors: Insights from the FAERS pharmacovigilance database

Evaluation of the anti-tumor effect of gambogic acid loaded macrophage membranes nanoparticles combined with radiotherapy and anti-PD-1mAb in the colorectal cancer with liver metastasis model.

Recurrent respiratory papillomatosis (RRP) is a benign, HPV 6/11-driven airway disease with frequent recurrences, often requiring multiple surgeries and imposing significant clinical and economic burdens. This narrative review synthesizes evidence from 2010–2025 on epidemiology, pathogenesis, clinical features, and therapies, emphasizing advances like bevacizumab, immune checkpoint inhibitors, and gene therapy (PRGN-2012, announced for FDA approval as Papzimeos™ on August 14, 2025). A structured literature search in PubMed, Scopus, and Web of Science identified 26 studies (clinical trials, cohorts, reviews). Key findings: HPV vaccination reduced juvenile RRP (JoRRP) incidence by >90% in vaccinated populations (e.g., Australia). Bevacizumab prolongs surgery-free intervals (up to 85% response rate systemically), while PRGN-2012 achieved a 51% complete response (no surgery for ≥12 months) with sustained benefits >2 years and mild adverse events, pending confirmation in peer-reviewed publications. INO-3107 reduced mean surgeries from 4.1 to 0.9 over two years, with an 86% overall response rate (ORR) in Year 2. Traditional adjuvants like cidofovir remain relevant in low-resource settings. Multimodal strategies (surgery, anti-angiogenics, immunotherapy) shift toward disease modification. Enhanced vaccination and biomarker research are crucial for global control.

A biomaterial-based platform of pancreatic cancer reveals kallikrein-related peptidase 6 (KLK6) as a mediator of neutrophil recruitment and immunosuppression.

Radiation-induced glioblastoma stem cell-mediated T cell exhaustion via EGR1-Gal3-LAG3 axis in glioblastoma.

Prognostic and immunological significance of tryptophan metabolic enzymes across endometrial cancer molecular subtypes.

Microbiota and cancer immunotherapy: Mechanisms, clinical implications, and precision therapeutics.

The central role of IL-17 in cancer stemness and immune evasion: A novel axis for overcoming immune checkpoint inhibitor resistance.

Simple porphyrin nanoparticles for combined photo-immunotherapy of colorectal cancer.